Â鶹ŮÓÅ

New data illustrating the health benefits of Novo Nordisk’s obesity drug Wegovy puts insurers in the increasingly uncomfortable position of justifying their refusal to pay for the new class of injectable weight-loss treatments known as GLP1 drugs. (Lisa Jarvis, 6/8)

The landmark approval of the first pill for postpartum depression offers an important new treatment for the 1 in 7 new mothers who experience postpartum depression. (Lisa Jarvis, 8/8)

Up to 1 in 7 new mothers suffer from postpartum depression, a serious mental health condition following childbirth. Yet despite the illness’s prevalence, there has been no oral medication to treat it specifically. (Leana S. Wen, 8/8)

The recent spotlight on shortages of essential medicines, such as cancer therapies and ADHD drugs, has brought attention to a longstanding public health crisis. Prescription drug shortages across drug classes have been on the radar of our governing bodies for decades. (Anna Sparrow, 8/9)

Drug shortages in the United States are at a record high. At least 14 essential generic cancer drugs are currently in shortage, forcing patients and doctors to make difficult decisions to delay or ration first-line treatments, or accept second-best treatments. ADHD treatments, antibiotics, children’s acetaminophen, and many other critical medicines are also in short supply. (Dana Brown and Christopher Morten, 8/9)

Recently, after years of pressure, advocates including author and philanthropist John Green scored victory against Johnson & Johnson over a patent on a key tuberculosis drug. The campaigners hope the move will give millions of people affected by tuberculosis in low- and middle-income countries access to the lifesaving medication bedaquiline. (Abdullahi Tsanni, 8/7)